Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601568219> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W2601568219 endingPage "4511" @default.
- W2601568219 startingPage "4511" @default.
- W2601568219 abstract "4511 Background: AZD3514 is a first in class, orally bio-available drug that inhibits androgen-dependent and –independent androgen receptor (AR) signaling through two distinct mechanisms; inhibition of ligand-driven nuclear AR translocation and down-regulation of AR levels. Methods: A rolling six design was employed initially using a once a day (QD) schedule (A). PK assessments led to a change to twice daily (BD) dosing (B) to increase exposure. PK profiles were studied over 96 hours after a single dose and over 24 hours at start of/following 21 days continuous dosing. PD analyses included PSA and CTC quantification. Results: 49 CRPC patients (pts) have been treated with escalating doses of AZD3514 (A 35 pts, B 14 pts). Starting doses were 100 mg (A) and 1000 mg (B). The AZD3514 formulation was switched from capsules to tablets at 1000mg (QD). 2000mg BD was considered non-tolerable due to multiple grade 2 toxicities (nausea [N], vomiting [V], fatigue). No adverse events (AEs) met the DLT definition. The most frequent drug-related AE’s were N; G1/2 36/49 (73%), G3 2/49 (4%) and V; G1/2 24/49 (49%) & G3 3/49 (6%). N/V were managed with oral anti-emetics. Dose proportional increases in plasma concentrations were observed following a single dose. Geometric mean (%CV) Cmax and AUC at MTD were 9,608 (38.5) ng/mL and 61,734 (40.6) ng.hr/mL, respectively. Compared with single dose continuous dosing led to a mean decrease of 26% in exposure. Maximum PSA and CTC declines are summarized below. Objective soft tissue responses per RECIST1.1 were observed in 2/26 (8%) pts. One pt with abiraterone resistant disease remained on study for 19 months. At 6 and 12 months 21 (43%) and 8 (16%) pts remained on study without evidence of bone or soft tissue progression, respectively. Conclusions: AZD3514 has antitumor activity in patients with advanced CRPC. Clinical trial information: NCT01162395. [Table: see text]" @default.
- W2601568219 created "2017-04-07" @default.
- W2601568219 creator A5000418012 @default.
- W2601568219 creator A5037530844 @default.
- W2601568219 creator A5041581270 @default.
- W2601568219 creator A5042313475 @default.
- W2601568219 creator A5048796030 @default.
- W2601568219 creator A5050190405 @default.
- W2601568219 creator A5052694721 @default.
- W2601568219 creator A5055792960 @default.
- W2601568219 creator A5057124877 @default.
- W2601568219 creator A5057407696 @default.
- W2601568219 creator A5057840141 @default.
- W2601568219 creator A5062420789 @default.
- W2601568219 creator A5065833805 @default.
- W2601568219 creator A5072099525 @default.
- W2601568219 creator A5076098983 @default.
- W2601568219 creator A5082019401 @default.
- W2601568219 creator A5087705803 @default.
- W2601568219 date "2013-05-20" @default.
- W2601568219 modified "2023-10-04" @default.
- W2601568219 title "A first-in-human study of the oral selective androgen receptor down-regulating drug (SARD) AZD3514 in patients with castration-resistant prostate cancer (CRPC)." @default.
- W2601568219 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.4511" @default.
- W2601568219 hasPublicationYear "2013" @default.
- W2601568219 type Work @default.
- W2601568219 sameAs 2601568219 @default.
- W2601568219 citedByCount "7" @default.
- W2601568219 countsByYear W26015682192014 @default.
- W2601568219 countsByYear W26015682192016 @default.
- W2601568219 countsByYear W26015682192020 @default.
- W2601568219 crossrefType "journal-article" @default.
- W2601568219 hasAuthorship W2601568219A5000418012 @default.
- W2601568219 hasAuthorship W2601568219A5037530844 @default.
- W2601568219 hasAuthorship W2601568219A5041581270 @default.
- W2601568219 hasAuthorship W2601568219A5042313475 @default.
- W2601568219 hasAuthorship W2601568219A5048796030 @default.
- W2601568219 hasAuthorship W2601568219A5050190405 @default.
- W2601568219 hasAuthorship W2601568219A5052694721 @default.
- W2601568219 hasAuthorship W2601568219A5055792960 @default.
- W2601568219 hasAuthorship W2601568219A5057124877 @default.
- W2601568219 hasAuthorship W2601568219A5057407696 @default.
- W2601568219 hasAuthorship W2601568219A5057840141 @default.
- W2601568219 hasAuthorship W2601568219A5062420789 @default.
- W2601568219 hasAuthorship W2601568219A5065833805 @default.
- W2601568219 hasAuthorship W2601568219A5072099525 @default.
- W2601568219 hasAuthorship W2601568219A5076098983 @default.
- W2601568219 hasAuthorship W2601568219A5082019401 @default.
- W2601568219 hasAuthorship W2601568219A5087705803 @default.
- W2601568219 hasConcept C112705442 @default.
- W2601568219 hasConcept C121608353 @default.
- W2601568219 hasConcept C126322002 @default.
- W2601568219 hasConcept C126894567 @default.
- W2601568219 hasConcept C197934379 @default.
- W2601568219 hasConcept C22979827 @default.
- W2601568219 hasConcept C2777288759 @default.
- W2601568219 hasConcept C2777911890 @default.
- W2601568219 hasConcept C2780192828 @default.
- W2601568219 hasConcept C2780580376 @default.
- W2601568219 hasConcept C2780852908 @default.
- W2601568219 hasConcept C61367390 @default.
- W2601568219 hasConcept C71315377 @default.
- W2601568219 hasConcept C71924100 @default.
- W2601568219 hasConcept C98274493 @default.
- W2601568219 hasConceptScore W2601568219C112705442 @default.
- W2601568219 hasConceptScore W2601568219C121608353 @default.
- W2601568219 hasConceptScore W2601568219C126322002 @default.
- W2601568219 hasConceptScore W2601568219C126894567 @default.
- W2601568219 hasConceptScore W2601568219C197934379 @default.
- W2601568219 hasConceptScore W2601568219C22979827 @default.
- W2601568219 hasConceptScore W2601568219C2777288759 @default.
- W2601568219 hasConceptScore W2601568219C2777911890 @default.
- W2601568219 hasConceptScore W2601568219C2780192828 @default.
- W2601568219 hasConceptScore W2601568219C2780580376 @default.
- W2601568219 hasConceptScore W2601568219C2780852908 @default.
- W2601568219 hasConceptScore W2601568219C61367390 @default.
- W2601568219 hasConceptScore W2601568219C71315377 @default.
- W2601568219 hasConceptScore W2601568219C71924100 @default.
- W2601568219 hasConceptScore W2601568219C98274493 @default.
- W2601568219 hasIssue "15_suppl" @default.
- W2601568219 hasLocation W26015682191 @default.
- W2601568219 hasOpenAccess W2601568219 @default.
- W2601568219 hasPrimaryLocation W26015682191 @default.
- W2601568219 hasRelatedWork W1992189987 @default.
- W2601568219 hasRelatedWork W2004706469 @default.
- W2601568219 hasRelatedWork W2051764329 @default.
- W2601568219 hasRelatedWork W2074629895 @default.
- W2601568219 hasRelatedWork W2080969318 @default.
- W2601568219 hasRelatedWork W2156337883 @default.
- W2601568219 hasRelatedWork W2375012438 @default.
- W2601568219 hasRelatedWork W2417803418 @default.
- W2601568219 hasRelatedWork W2604484584 @default.
- W2601568219 hasRelatedWork W3207313530 @default.
- W2601568219 hasVolume "31" @default.
- W2601568219 isParatext "false" @default.
- W2601568219 isRetracted "false" @default.
- W2601568219 magId "2601568219" @default.
- W2601568219 workType "article" @default.